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BACKGROUND: Identifying and addressing the requirements of cancer survivors is currently a high priority for the NHS, yet little is
known about the population of cancer survivors in the United Kingdom.
METHODS: Data from cancer registries in England, Northern Ireland, Scotland and Wales were analysed to provide limited-duration
prevalence estimates for 2004. Log-linear regression models were used to extend these to complete prevalence estimates. Trends in
prevalence from 2000 to 2004 were used to project complete prevalence estimates forward from 2004 to 2008.
RESULTS: We estimated that in total, there were 2 million cancer survivors in the United Kingdom at the end of 2008, B3% of
the population overall and 1 in 8 of those aged 65 years and more. Prostate and female breast cancers were the most prevalent.
The number of cancer survivors is increasing by B3% each year. Estimates are also provided by time since diagnosis.
CONCLUSION: These estimates are the most up-to-date available, and as such will be useful for statutory and voluntary sector
organisations that are responsible for planning and providing treatment and support to cancer survivors in the United Kingdom.
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Cancer survivors are defined as those people living with a
diagnosis of cancer from some point in their past. Cancer
prevalence is expressed as the number or proportion of cancer
survivors in a population at a given point in time. Identifying and
addressing the requirements of cancer survivors in England is a
high priority in the Cancer Reform Strategy (Department of
Health, 2007) and, as a result, the National Cancer Survivorship
Initiative was set up in 2008. Similar initiatives are being
established in Northern Ireland, Scotland and Wales. However,
little is known about the size and demography of the population of
cancer survivors in the United Kingdom; the most recent estimate,
provided by the EUROPREVAL project (Forman et al, 2003), was
for 1992.
In this paper, we provide up-to-date estimates of cancer
prevalence in the United Kingdom at the end of 2008 using cancer
registry data. Cancer survivors may have been recently diagnosed
and in active treatment, or they may have survived long enough to
be considered cured. However, in our analysis, we do not make
such distinctions; once an individual is diagnosed with cancer, he
(or she) is considered a survivor until death. We adopt this
approach because, first, a diagnosis of cancer may affect a person’s
life in different ways (mental health, fear of recurrence, financial
hardship, relationship issues, etc.), and its effects may be felt for
many years after diagnosis. Second, this approach is practical as
the currently available cancer registration data do not readily allow
survivors to be classified as having active disease, in remission or
cured of their cancer.
MATERIALS AND METHODS
The eight cancer registries in England, together with the national
registries in Scotland, Wales and Northern Ireland, provided
anonymised records of all registered malignant neoplasms (ICD-10
C00-C97) diagnosed in the residents of those countries, excluding
non-melanoma skin cancer (ICD-10 C44) as it is not covered
systematically by all registries. Each record included demographic,
tumour, diagnosis, follow-up and death details. Data were available
for the periods 1971–2004 for England, 1971–2005 for Scotland,
1990–2006 for Wales and 1993–2006 for Northern Ireland.
All tumours apparently diagnosed in patients over the age of
99 years were excluded (B0.04% of the total), leaving 7.7 million
registration records for analysis.
The UK cancer registries receive death notifications from the
Office for National Statistics (ONS) (England and Wales) and the
General Register Offices (Scotland and Northern Ireland), which
are then matched to the cancer registration records, although a
small percentage are never so matched. The patients associated
with these ‘lost-to-follow-up’ registrations are at face value,
effectively immortal, resulting in apparent cancer survivors of
a much higher age than we know to be likely. The proportion
of registrations lost to follow-up in European registries is believed
to be o1% (Capocaccia et al, 1999), but is unknown in the
United Kingdom. Therefore, in computing prevalence, cancer
survivors were censored at the age of 105 years.
Cancer prevalence can be expressed as the number of prevalent
tumours or the number of prevalent patients. As each patient may,
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yin their lifetime, be diagnosed with more than one tumour, patient
prevalence will always be lower than tumour prevalence. This
analysis focuses on patient prevalence, and only the first diagnosed
malignant neoplasm (excluding non-melanoma skin cancer) in
each patient was considered.
Although cancer registry data for Scotland, Wales and Northern
Ireland were available for the years 2005 and 2006, for England it
was available only up to 2004 at the time of analysis. For this
reason, we used the most recent index date common to all data,
that is, 31 December 2004. The number of cancer patients alive on
this date was counted and disaggregated by country of residence,
sex, age group on the index date (0–44, 45–64 and 65þ years),
number of years since diagnosis and the following broad groups of
cancer diagnoses:
(1) colon, rectum and anus (ICD-10 C18-C21),
(2) lung, bronchus and trachea (ICD-10 C33-C34),
(3) female breast (ICD-10 C50),
(4) prostate (ICD-10 C61),
(5) all other malignant neoplasms excluding non-melanoma skin
cancer (ICD-10 C00-C97 excluding C44 and (1) to (4)).
Death-Certificate-Only (DCO) registrations are those for which
the only source of patient/tumour information is the death
certificate stating the cause of death. These registrations lack
much information, particularly the actual date of diagnosis. An
unknown proportion of the DCO registrations since the index date
will pertain to patients diagnosed before, and alive on, the index
date. We have not attempted to estimate this proportion, and
therefore they are not included in our prevalence estimates.
Complete prevalence
N-year limited-duration prevalence counts include only those
survivors diagnosed in the last N years before the index date.
Complete prevalence includes all cancer survivors, regardless of
when they were diagnosed. It is not possible to directly count
complete prevalence on the basis of registry data, given that no UK
cancer registry has been collecting data for a sufficiently long
period of time. Instead, we estimated complete prevalence by
extrapolating from limited-duration prevalence.
With an index date of 31 December 2004, the available cancer
registry data provided 34-year prevalence estimates for England
and Scotland, 15-year estimates for Wales and 12-year estimates
for Northern Ireland. To extend these limited-duration estimates
to complete estimates, a negative binomial regression model with a
log-link function was constructed for each type of cancer, sex and
age group (0–44, 45–64, 65þ years). The prevalence count on the
index date was the response variable, and the predictor variables
were country of residence and number of years since diagnosis.
Given that our primary objective was to obtain a reasonable
estimate for the number of people surviving at least 12 years
(Northern Ireland) and 15 years (Wales) beyond diagnosis, data
pertaining to recent diagnoses (years since diagnosis p5) were not
used in the models. Prostate cancer was treated as a special case
and modelled in two stages; first, for years of diagnosis between
1992 and 1999 and second, for all years before 1992. We also
included an offset term in all models, defined as the log of the
number of people in a given country who could contribute to
the prevalence count, taking into account the age group being
considered and the fact that years since diagnosis cannot exceed
age on the index date. The models were run using the PROC
GENMOD procedure in SAS (SAS Institute Inc, Cary, NC, USA).
The validity of the regression models was tested by initially
excluding data for Scotland covering years of diagnosis between
1971 and 1992, and by comparing the modelled estimates with the
actual data for those years. Furthermore, we compared the
published estimated ratios of 15-year prevalence to complete
prevalence (the completeness index) in England and Scotland
(Forman et al, 2003) with those of our own (Table 1).
Trends
Through an analysis of recent trends in observed cancer
prevalence, we projected estimates of complete cancer prevalence
in the United Kingdom from 31 December 2004 forward to 2008.
We used the combined data from England and Scotland covering
diagnoses between 1971 and 2004 to estimate trends in limited-
duration prevalence during the years 2000–2004, for each site and
sex. Log-linear functions, considered appropriate for short-term
projections, were fitted to the trend data and provided estimates of
the annual growth in cancer survivor numbers that we expected
from 2004 to 2008. The following assumptions were made:
(1) the yearly rates of change of cancer prevalence in England and
Scotland combined can be applied to each country in the
United Kingdom;
(2) cancer prevalence in each age group (0–44, 45–64 and 65þ
years) is changing at the same rate as overall prevalence;
(3) complete prevalence is changing at the same rate as 30-year
prevalence.
Estimated prevalence counts were converted to proportions of
the population by using the mid-year ONS population estimates
for 2007; these were the most recently available estimates and
likely to be only slightly lower than the actual population at the
end of 2008 (ONS, 2008a).
RESULTS
Tables 2 and 3 and Figure 2 present complete prevalence – the sum
of observed prevalence from the years of diagnosis that were
available in our data and modelled prevalence from those that were
not. We have indicated by italicised text in Tables 2–4 those
estimates for which more than 20% of the total is derived from
modelling. We estimated that by the end of 2008, there were just
over 2 million cancer survivors in the United Kingdom (59%
women and 41% men), equating to B2.7% of the male and 3.8% of
the female population. Table 2 shows the variation in prevalence
by country and cancer sites. Wales had the most number of cancer
Table 1 Comparison of 15-year completeness indices, by cancer site
and sex
Maddams et al
a EUROPREVAL
b
Males
Colon, rectum and anus 0.81 0.87
c
Lung, bronchus and trachea 0.58 0.73
d
Prostate 0.95 0.97
All malignant neoplasms
e 0.78 0.82
Females
Breast 0.74 0.80
Colon, rectum and anus 0.74 0.80
Lung, bronchus and trachea 0.77 0.79
All malignant neoplasms
e 0.70 0.72
ICD¼International Classification of Diseases. The 15-year completeness index is
defined as 15-year prevalence divided by complete prevalence.
a15-year prevalence
divided by estimated complete prevalence in the United Kingdom. Index date: 31
December 2004.
bAverage 15-year completeness index for prevalence as estimated
using data from South Thames, West Midlands, Yorkshire and Scotland cancer
registries. Index date: 31 December 1992. Published by Forman et al (2003), Ann
Oncol 14: 648–654.
cAverage of indices for cancers of the colon and rectum.
dCancer
of the lung only.
eExcluding non-melanoma skin cancer (ICD-10 C44).
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Ireland had the fewest (2.4% men and 3.4% women).
Prostate and female breast cancers were the most prevalent, and
accounted for 31 and 46% of male and female cancer prevalence,
respectively. Of the cancers studied in this paper, lung cancer was
the least prevalent. Figure 1 shows, for each sex, the proportions
of total incident cases, cancer deaths and cancer survivors that
are accounted for by colorectal, lung, prostate and female breast
Table 2 Prevalence of cancer on 31 December 2008 in the United Kingdom, by country of residence
England Scotland Wales Northern Ireland United Kingdom
Males
Colon, rectum and anus 100608 (401) 11522 (464) 6921 (476) 3480 (404) 122531 (410)
Lung, bronchus and trachea 32034 (128) 3760 (151) 1889 (130) 1058 (123) 38741 (130)
Prostate 215654 (859) 19163 (771) 13312 (916) 5307 (616) 253436 (847)
All other malignant neoplasms
a 334147 (1330) 36853 (1483) 22998 (1582) 10482 (1216) 404480 (1352)
All malignant neoplasms
a 682443 (2717) 71298 (2868) 45120 (3103) 20327 (2358) 819188 (2738)
Females
Breast 460041 (1771) 46211 (1738) 29838 (1955) 12908 (1439) 548998 (1768)
Colon, rectum and anus 92439 (356) 11419 (430) 5885 (386) 3542 (395) 113285 (365)
Lung, bronchus and trachea 19634 (76) 3215 (121) 1239 (81) 693 (77) 24781 (80)
All other malignant neoplasms
a 409284 (1576) 46607 (1753) 26683 (1749) 13690 (1526) 496264 (1598)
All malignant neoplasms
a 981398 (3778) 107452 (4042) 63645 (4171) 30833 (3437) 1183328 (3810)
ICD¼International Classification of Diseases. The number of survivors (crude proportion per 100000) is indicated; the sum of observed prevalence was available from cancer
registry data, whereas modelled prevalence was not. Italicised numbers are those that are based on estimates of prevalence in 2004 that were at least 20% modelled.
aExcluding
non-melanoma skin cancer (ICD-10 C44).
Table 3 Prevalence of cancer on 31 December 2008 in the United Kingdom, by time since diagnosis
0–1 years 1–5 years 5–10 years 10–20 years 420 years Total
Males
Colon, rectum and anus 14619 (49) 38075 (127) 31162 (104) 24534 (82) 14141 (47) 122531 (410)
Lung, bronchus and trachea 8263 (28) 7850 (26) 3810 (13) 4769 (16) 14049
a (47)
a 38741 (130)
Prostate 37967 (127) 125470 (419) 61376 (205) 22601 (76) 6022 (20) 253436 (847)
All other malignant neoplasms
b 40891 (137) 97529 (326) 87008 (291) 98726 (330) 80326 (269) 404480 (1352)
All malignant neoplasms
b 101740 (340) 268924 (899) 183356 (613) 150630 (504) 114538 (383) 819188 (2738)
Females
Breast 42432 (137) 140111 (451) 128672 (414) 145035 (467) 92748 (299) 548998 (1,768)
Colon, rectum and anus 11309 (36) 30341 (98) 27128 (87) 25532 (82) 18975 (61) 113285 (365)
Lung, bronchus and trachea 6905 (22) 7255 (23) 3671 (12) 2682 (9) 4268 (14) 24781 (80)
All other malignant neoplasms
b 40655 (131) 109179 (352) 96400 (310) 119366 (384) 130664 (421) 496264 (1598)
All malignant neoplasms
b 101301 (326) 286886 (924) 255871 (824) 292615 (942) 246655 (794) 1183328 (3810)
ICD¼International Classification of Diseases. The number of survivors (crude proportion per 100000) is indicated; the sum of observed prevalence was available from cancer
registry data, whereas modelled prevalence was not. Italicised numbers are those that are based on estimates of prevalence in 2004 that were at least 20% modelled.
aThe
estimate of the number of long-term male lung cancer survivors (420 years from diagnosis) is likely over-estimated; see the section ‘Discussion’ for details. A more plausible
figure is 6000 (20 per 100000).
bExcluding non-melanoma skin cancer (ICD-10 C44).
Table 4 Prevalence of cancer on 31 December 2008 in the United Kingdom, by age
0–44 years 45–64 years 65+ years Total
Males
Colon, rectum and anus 2091 (11) 25690 (343) 94750 (2238) 122531 (410)
Lung, bronchus and trachea 441 (2) 6643 (89) 31657 (748) 38741 (130)
Prostate 181 (1) 34511 (461) 218744 (5168) 253436 (847)
All other malignant neoplasms
a 68539 (377) 125077 (1671) 210864 (4982) 404480 (1352)
All malignant neoplasms
a 71252 (392) 191921 (2563) 556015 (13136) 819188 (2738)
Females
Breast 25428 (143) 208076 (2694) 315494 (5688) 548998 (1768)
Colon, rectum and anus 2134 (12) 19723 (255) 91428 (1648) 113285 (365)
Lung, bronchus and trachea 530 (3) 5904 (76) 18347 (331) 24781 (80)
All other malignant neoplasms
a 67530 (380) 151756 (1965) 276978 (4994) 496264 (1598)
All malignant neoplasms
a 95622 (538) 385459 (4990) 702247 (12661) 1183328 (3810)
ICD¼International Classification of Diseases. The number of survivors (crude proportion per 100000) is indicated; the sum of observed prevalence was available from cancer
registry data, whereas modelled prevalence was not. Italicised numbers are those that are based on estimates of prevalence in 2004 that were at least 20% modelled.
aExcluding
non-melanoma skin cancer (ICD-10 C44).
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ycancers. For both men and women, colorectal cancer accounted
for approximately 10–15% of all the three measures. In contrast,
for men, lung cancer accounted for 15% of all newly diagnosed
cancers, 25% of cancer deaths and for only 5% of cancer
prevalence. A similar pattern was seen for female lung cancer,
which accounted only for 2% of cancer prevalence in women.
Prostate and female breast cancers provided further contrasts, the
latter accounting for 31% of newly diagnosed cancers, 17% of
cancer deaths and for 46% of cancer prevalence among women.
Table 3 presents cancer prevalence in the United Kingdom, by
the number of years that had passed since diagnosis. This varied
across the sexes and cancer sites, as illustrated in Figure 2. Overall,
female cancer survivors tended to be further from their diagnosis
than males, 67% of them being diagnosed more than 5 years
earlier, compared with 55% of males.
Table 4 shows the variation of cancer prevalence with age. Less
than 1% of the UK population aged o45 years at the end of 2008
were cancer survivors, compared with 13% of those aged 65 years and
more. There were twice as many female survivors aged between 45
and 64 years as there were males, largely because of the dominance of
female breast cancer that accounted for 54% of female survivors in
this age range. The most prevalent types of cancer in those aged 65
years and more were prostate and female breast cancers; 5% of males
and 6% of females in this age group were survivors of these cancers.
Figure 3 shows the trends in 1-, 5-, 10-, 20- and 30-year limited-
duration prevalence during the period 2000–2004, projected to
2008. Only male lung cancer did not show an increasing trend, the
total number of survivors declining by 1.4% per year. By far, the
most rapidly increasing prevalence is that of prostate cancer,
the total number of survivors increasing by 9.8% per year. Overall,
the number of cancer survivors increased by 3.8% per year for men
and 2.7% for women.
DISCUSSION
For producing our prevalence estimates, we have, where available,
used incidence and follow-up data collected by cancer registries in
the United Kingdom. We have not adjusted our estimates for DCO
registrations that occurred after the index date. DCOs account for
o5% of all registrations in the UK and most often relate to patients
who have died soon after diagnosis. We have therefore assumed that
their effect on cancer prevalence is negligible. We have not
attempted to estimate the proportion lost to follow-up nor
emigrations. Nor have we been able to include UK immigrants
with a diagnosis of cancer pre-dating their move. To a certain
extent, the effects of including emigrants and excluding immigrants
will cancel each other out.
For estimating the number of survivors from a period before
cancer registration in their country, we have developed log-linear
regression models for the prevalence count as a function of time
since diagnosis. Treating prevalence in this manner as an isolated
statistic does not explicitly model the joint effect of incidence and
survival, and is based on the observation that the relationship
between the number of years since diagnosis and the number of
prevalent cases is approximately log linear (Phillips et al, 2002).
However, as this relationship is not log linear for prostate cancer,
the regression model was applied in two stages. This accounted for
the introduction of PSA testing in the early 1990s, which effectively
changed the definition of the disease with many more localised
tumours diagnosed (Evans and Moller, 2003). The number of
prostate cancer survivors is increasing at the fastest rate of cancers
studied here, by almost 10% each year. As the changes in incidence
and survival caused by the introduction of PSA testing are
relatively recent, we expect their numbers to increase at a similar
rate for some years to come, until a situation is reached in which
very few were diagnosed in the era before PSA testing.
Table 1 shows that our estimated 15-year completeness indices
for 2004 were consistently lower than those previously published
for 1992 (Forman et al, 2003). The differences in the completeness
index are consistent with the improvements in survival observed
between 1992 and 2004 for many cancers (Cancer Research UK,
2007; Rachet et al, 2008). Increases in survival rates result in a
larger proportion of long-term cancer survivors and therefore, in a
smaller completeness index. Although most differences in these
indices were small, for male lung cancer, the difference was large
(0.58 compared with the published estimate of 0.73). Despite the
two estimates relating to different index dates and the changes in
lung cancer incidence between the two dates, we would not expect
such a large discrepancy. For lung cancer, as with prostate cancer,
the number of survivors is not a log-linear function of years since
diagnosis. Owing to its poor prognosis, lung cancer prevalence is
dominated by short-term survivors (Figure 2c); hence, we believe
that our models have over-estimated the number of long-term
male survivors. If we were to use a ratio of 0.73, then we would
produce an estimate of 6000 (rather than 14000) male lung cancer
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Figure 1 Proportion of total incidence
1, mortality
2 and prevalence
3 that is accounted for by selected cancers. (A) Males; (B) females.
1Incidence
in England, 2006; data from National Cancer Information Service (NCIS);
2Mortality in England, 2005; data from NCIS;
3Prevalence in the
United Kingdom, 2008.
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years since their diagnosis. This estimate seems more plausible,
especially when compared with the report stating that, in the
Northern European countries in 1992, only 31% of male lung
cancer prevalence was accounted for by survivors who were more
than 10 years from diagnosis Moller et al (2003).
We have adopted a pragmatic approach to the modelling used in
this study. Owing to the long time series of registry data in the
United Kingdom, the majority of the estimates presented contain
only a small contribution of modelled data. This contribution is
most significant in the estimates for Northern Ireland and, to a
lesser extent, for Wales. With 34-years of data available for
England and Scotland, the modelled proportions of the complete
prevalence estimates were typically B5% for men and 8% for
women. Therefore, we believe these estimates to be robust and fit
for the purpose.
Substantial results of the analysis
There are B2 million cancer survivors in the United Kingdom
today. In those aged 65 years and more, B13% of the population
are cancer survivors. Approximately one in three of the UK
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Figure 2 Prevalence of cancer in the United Kingdom on 31 December 2004, by number of years since diagnosis and age. (A) Males: colon, rectum and
anus; (B) females: colon, rectum and anus; (C) males: lung, bronchus and trachea; (D) females: lung, bronchus and trachea; (E) prostate; (F) females: breast.
Prevalence of cancer in the United Kingdom on 31 December 2004: the sum of observed prevalence was available from national cancer registry data,
whereas modelled prevalence was not.
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ypopulation will be diagnosed with cancer during their lifetime and
one in four will die from it (Cancer Research UK, 2008); we can
also state that one in eight of those aged 65 years and more are
living with or beyond cancer.
Our overall estimate of 2 million is far higher than that of 1.2
million at the end of 1992 (Forman et al,2 0 0 3 ) .H o w e v e r ,w eh a v e
found that in recent years the absolute number of cancer survivors
in the United Kingdom has increased by B3% per annum, and that
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Figure 3 Trends and projections of limited-duration cancer prevalence in the United Kingdom, 2000–2008. (A) Males: colon, rectum and anus;
(B) females: colon, rectum and anus; (C) males: lung, bronchus and trachea; (D) females: lung, bronchus and trachea; (E) prostate; (F) females: breast;
(G) All malignant neoplasms
1; males. (H) All malignant neoplasms
1; females;
1Excluding non-melanoma skin cancer (ICD-10 C44).
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period between 1992 and 2008, then the two figures are consistent.
Not only is cancer prevalence increasing overall but the relative
prevalence of different types of cancer is also changing. For
example, prostate and female breast cancers have shown some of the
largest increases in incidence and improvements in survival of all
cancers in the United Kingdom since 1992 (Cancer Research UK,
2007), resulting in the proportion of total sex-specific prevalence
accounted for by each increasing from 14 and 37% in 1992 (Forman
et al, 2003) to 31 and 46% in 2008, respectively.
The number of cancer survivors varies within the United
Kingdom, with Northern Ireland having the lowest prevalence
proportion and Wales the highest. We have not presented age-
specific proportions for each country, but the observed differences
are, at least in part, attributable to the different age structures in
each country; Northern Ireland has the youngest population (63%
aged under 45 years; UK average of 59%) and Wales has the oldest
population (18% aged 65 years and more; UK average of 16%).
Different patterns of adopting PSA testing in the early 1990s
resulted in higher detection rates of prostate cancer in Britain,
compared with those in Northern Ireland. Consequently, recorded
prostate cancer incidence between 1993 and 2003 remained lower
in Northern Ireland than in the rest of the United Kingdom
(Fitzpatrick et al, 2006).
In areas where cancer registration is less comprehensive than in
the United Kingdom, models of incidence and survival rates have
been developed to estimate cancer prevalence (Capocaccia and De
Angelis, 1997). Owing to the large amount of cancer registry data
available, little modelling was required, and for simplicity our
approach treated prevalence as an isolated statistic. Nevertheless, it
is important to appreciate that it is not an isolated measure, and
that historical incidence and survival figures combine to produce
the prevalence figures existing today. Figure 1 provides an
illustration of this interaction: a cancer such as lung cancer, with
a poor prognosis accounts for a very small proportion of prevalent
cases, despite being one of the most commonly diagnosed cancers.
Conversely, prostate and female breast cancers, with relatively good
prognoses, account for larger proportions of cancer survivors than
they do for new incident cases. Changes in incidence and survival
(brought about by changes in lifestyle, population structure and
health-service policy) will therefore have significant consequences
for the prevalence of cancer. For example, since the 1970s, the
number of smokers in the UK male population decreased from
B50% to B20% (ONS, 2008b), resulting in a decrease in male lung
cancer incidence and, in turn, a decrease in prevalence.
The previous most recent UK estimates of cancer prevalence
were related to 1992 (Forman et al, 2003), since then, as we have
shown, cancer prevalence has changed markedly. Therefore, our
estimates are highly relevant for both statutory and voluntary
sector organisations that are responsible for planning and
providing treatment and support to cancer survivors in the United
Kingdom. In the coming years, cancer prevalence will continue to
increase as a result of the growing and ageing population of the
United Kingdom, increased detection of cancer and improving
survival rates. We estimated that, overall, the annual rate of
increase in the number of cancer survivors is currently B3%, and
we anticipate that this rate of increase will continue in the near
future. Issues surrounding care and support for cancer survivors
should, therefore, remain high on the public health agenda, with
analysis and projections of cancer incidence, prevalence and
mortality becoming increasingly central to resource-planning
decisions. Cancer detection and treatment resources tend to focus
on the most commonly diagnosed types of cancer, or major killers,
but for cancer survivors, the most significant cancers are those
with both a high incidence rate and a relatively good prognosis
(such as prostate cancer and female breast cancer).
Knowledge of the natural progression of a particular type of
cancer, together with the analysis of prevalence by time since
diagnosis, gives some indication of different phases of survivor-
ship, but does not fully show the extent to which survivors require,
or are receiving, care and support. Many survivors will be newly
diagnosed and in active treatment, others may be in a state of
remission or recurrence with or without late effects of treatment,
others may be receiving palliative care, whereas some may
consider themselves to be completely free of cancer. Awareness
of these differences is important when assessing the health-care
burden of cancer, the financial costs of which are the highest
during initial treatment and end of life care (Brown et al, 1999).
We intend to extend the work presented in this paper in order to
provide additional details about the different phases of survivor-
ship and to analyse the factors that influence cancer prevalence
over time.
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